Polycystic Kidney Disease with Hyperinsulinemic Hypoglycemia Caused by a Promoter Mutation in Phosphomannomutase 2-Reference-Cited by-同舟云学术

Polycystic Kidney Disease with Hyperinsulinemic Hypoglycemia Caused by a Promoter Mutation in Phosphomannomutase 2

Published:2017-04-03 Issue:8 Volume:28 Page:2529-2539
ISSN:1046-6673
Container-title:Journal of the American Society of Nephrology
language:en
Short-container-title:JASN

Author:

Cabezas Oscar Rubio,Flanagan Sarah E.,Stanescu Horia,García-Martínez Elena,Caswell Richard,Lango-Allen Hana,Antón-Gamero Montserrat,Argente Jesús,Bussell Anna-Marie,Brandli Andre,Cheshire Chris,Crowne Elizabeth,Dumitriu Simona,Drynda Robert,Hamilton-Shield Julian P,Hayes Wesley,Hofherr Alexis,Iancu Daniela,Issler Naomi,Jefferies Craig,Jones Peter,Johnson Matthew,Kesselheim Anne,Klootwijk Enriko,Koettgen Michael,Lewis Wendy,Martos José María,Mozere Monika,Norman Jill,Patel Vaksha,Parrish Andrew,Pérez-Cerdá Celia,Pozo Jesús,Rahman Sofia A,Sebire Neil,Tekman Mehmet,Turnpenny Peter D.,Hoff William van’t,Viering Daan H.H.M.,Weedon Michael N.,Wilson Patricia,Guay-Woodford Lisa,Kleta Robert,Hussain Khalid,Ellard Sian,Bockenhauer Detlef

Publisher

American Society of Nephrology (ASN)

Subject

Nephrology,General Medicine

Reference42 articles.

1. Prenatal diagnosis of autosomal recessive polycystic kidney disease (ARPKD): Molecular genetics, clinical experience, and fetal morphology

3. Autosomal Recessive Polycystic Kidney Disease: A Hepatorenal Fibrocystic Disorder With Pleiotropic Effects

4. Consensus Expert Recommendations for the Diagnosis and Management of Autosomal Recessive Polycystic Kidney Disease: Report of an International Conference

5. Genetics of congenital hyperinsulinemic hypoglycemia.;Flanagan;Semin Pediatr Surg,2011

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Putative Looping Factor ZNF143/ZFP143 is an Essential Transcriptional Regulator with No Looping Function;2024-03-12

2. Glucose Dysregulation Associated with Hypoglycaemia in Childhood and Adolescence;Endocrinology;2024

3. Clinical and biochemical footprints of inherited metabolic diseases. XIV. Metabolic kidney diseases;Molecular Genetics and Metabolism;2023-11

4. The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis;Nefrología (English Edition);2023-11

5. Autosomal Recessive Polycystic Kidney Disease: Diagnosis, Prognosis, and Management;Advances in Kidney Disease and Health;2023-09